Pulmonary Arterial Hypertension Treatment Market Research, 2031
The global pulmonary arterial hypertension treatment market size was valued at $7,177.81 million in 2021, and is projected to reach $11,968.60 million by 2031, growing at a CAGR of 5.2% from 2021 to 2031. Pulmonary hypertension refers to the type of high blood pressure that mainly affects the arteries in the lungs and the right side of the heart. It is characterized by narrowed and blocked arteries and capillaries. Use of drugs such as endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs, and SGC stimulators helps to treat pulmonary arterial hypertension. They either help relax the muscles in the wall of the blood vessels, or increase the blood flow through the lungs, or reverse the effect of the substance in the walls of blood vessels, which caused them to narrow.
Get more information on this report
The key factors that drive the growth of the pulmonary arterial hypertension treatment market size include rise in prevalence of lung cancer and lung-related disorders; increase in geriatric population; and surge in adoption of technologically advanced medical devices across the world.
In addition, increase in prevalence of pulmonary artery hypertension, rise in awareness about pulmonary artery hypertension treatment among people, and growth in the geriatric population are the drivers that cause the expansion of the pulmonary artery hypertension market. Increase in R&D initiatives by the key market players, on the other hand, is expected to provide lucrative opportunities for the market players to invest, which may lead to the market growth. However, strict regulatory standards, and expensive development costs can hamper the market growth in the near future.
Impact of COVID-19 on Pulmonary Arterial Hypertension Treatment Market
The COVID-19 pandemic has proved to be an incomparable global public health emergency that has affected almost every industry, and the effects are expected to impact their growth during the forecast period. Several changes in consumer demand and behavior, buying habits, supply chain redirection, and significant government initiatives have been seen around the globe. The COVID-19 outbreak has positively impacted the pulmonary artery hypertension market, owing to increase in prevalence of COVID-19 infections with the patient who is already affected with pulmonary artery hypertension across the world. The diagnosis and treatment of pulmonary hypertension, as well as the observation of an elevated mortality risk in individuals with pulmonary artery hypertension, have all been significantly impacted by COVID-19. In addition, the pandemic has affected the way healthcare is provided in pulmonary hypertension because of the fragile nature of this group. Many of the improvements in pulmonary artery hypertension care that have been noticed are arguably positive and represent changes that were required long ago, despite the fact that they are the consequence of a period of great struggle and pain. According to American College of Cardiology, the U.S. survey of 77 pulmonary artery hypertension Comprehensive Care Centers, there were 2.1 cases of COVID-19 infection for every 1,000 pulmonary artery hypertension patients, which is comparable to the rate of COVID-19 infection in the whole U.S. population. However, mortality did seem to be higher at 12% despite the fact that COVID-19 did not appear to be more common in patients with pulmonary artery hypertension. In addition, 33% of COVID-19-infected patients with pulmonary artery hypertension required hospitalization.
The pulmonary arterial hypertension treatment market is segmented into by Drug Type, Type and Route of Administration.
Pulmonary arterial hypertension treatment industry is segmented into drug type, type, route of administration and region. On the basis of drug type, the market is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and SGC stimulators. On the basis of type, it is bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of route of administration, the market is further classified into oral, intravenous/ subcutaneous, and inhalational. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Drug Type
Prostacyclin and Prostacyclin Analogs segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.
By Drug Type
On the basis of drug type, the pulmonary arterial hypertension treatment industry is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and SGC stimulators. In 2021, the prostacyclin and prostacyclin analogs segment accounted for the largest pulmonary arterial hypertension treatment market share.
By Type
Branded segment is projected as one of the most lucrative segment.
By Type
On the basis of type, the market is bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. In 2021, the branded segment accounted for the largest pulmonary arterial hypertension treatment market share.
By Route Of Administration
Oral segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.
By Route of Administration
On the basis of route of administration, the market is further classified into oral, intravenous/subcutaneous, and inhalational. In 2021, the oral segment accounted for the largest share. The large share of this segment was attributed to increase in number of patient visits in hospital for diagnosis of various chronic diseases.
By Region
North America held a dominant position in 2021 and would continue to maintain the lead over the forecast period.
By Region
On the basis of region, North America accounted for a majority of the pulmonary artery hypertension market share in 2021 and is anticipated to remain dominant during the pulmonary arterial hypertension treatment market forecast period. This is attributed to rise in number of chronic disease cases, presence of key players and advancement in healthcare in the region.
Asia-Pacific is anticipated to witness lucrative growth, owing to increase in medical tourism, implementation of new ICT guidelines in Japan, investments, and reforms to modernize healthcare infrastructure of China, rapid growth in healthcare industry in India support the pulmonary arterial hypertension treatment market growth in this region.
Some of the major companies that operate in the global pulmonary artery hypertension market are Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pulmonary arterial hypertension treatment market analysis from 2021 to 2031 to identify the prevailing pulmonary arterial hypertension treatment market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the pulmonary arterial hypertension treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global pulmonary arterial hypertension treatment market trends, key players, market segments, application areas, and market growth strategies.
Pulmonary Arterial Hypertension Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 12 billion |
 Growth Rate | CAGR of 5.2% |
 Forecast period | 2021 - 2031 |
 Report Pages | 335 |
 By Type |
|
 By Route of Administration |
|
 By Drug Type |
|
 By Region |
|
 Key Market Players | Viatris Inc., Gilead Sciences, Inc., Johnson & Johnson, Sun Pharmaceutical Industries, Inc., Lupin Pharmaceuticals, Inc., Bayer AG, United Therapeutics Corporation, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc. |
Analyst Review
This section provides various opinions of top-level CXOs in the pulmonary arterial hypertension treatment market. In accordance with several interviews conducted, the pulmonary arterial hypertension treatment market is expected to witness significant growth in the future, owing to increase in prevalence of HIV associated pulmonary artery hypertension incidences, adoption in drugs and rise in key strategic developments.
According to the perspectives of CXOs, the global pulmonary arterial hypertension treatment market is expected to witness a steady growth in the future. Rise in geriatric population and increase in number of HIV population are the factors driving the market growth. In addition, rise in prevalence of infectious diseases such as COVID-19 infection across the world propels the growth of the market. However, side effects associated with drugs used to treat pulmonary artery hypertension are expected to hamper the growth of the market up to some extent during the forecast period.
On the contrary, rise in growth potential in developing countries and increase in number of product approvals are expected to provide opportunities for the growth of the global pulmonary arterial hypertension treatment market in the future.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in technological advancement and rise in prevalence of chronic diseases. Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR owing to rise in geriatric population during the forecast period.
The upcoming trends of Pulmonary Arterial Hypertension Treatment Market includes increase in the prevalence of geriatric population affected with pulmonary arterial hypertension; rise in prevalence of HIV cases and surge in healthcare expenditure
Hypertension is the leading application of Pulmonary Arterial Hypertension Treatment Market.
North America is the largest regional market for Pulmonary Arterial Hypertension Treatment market.
Pulmonary Arterial Hypertension Treatment is projected to reach $11,968.60 million by 2031, registering a CAGR of 5.2% from 2022 to 2031.
The major companies that operate in the global pulmonary arterial hypertension treatment market are Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.
The base year is 2021 in Pulmonary Arterial Hypertension Treatment market.
Yes, the Pulmonary Arterial Hypertension Treatment market report provides PORTER Analysis.
Loading Table Of Content...
Loading Research Methodology...
